Nuvalent, Inc. (NUVL) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cambridge, MA, United States. El CEO actual es James R. Porter.
NUVL tiene fecha de IPO 2021-07-29, 162 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $7.69B.
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company's lead programs include NVL-520, a brain-penetrant ROS1-selective inhibitor currently in Phase I development designed to overcome drug resistance mutations, and NVL-655, a brain-penetrant ALK-selective inhibitor in Phase I/II clinical trials addressing treatment resistance and brain metastases. Founded in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent is advancing precision oncology solutions for patients with ROS1 and ALK-driven cancers.
